<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722917</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-379_201</org_study_id>
    <secondary_id>U1111-1125-0948</secondary_id>
    <nct_id>NCT00722917</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-center Study to Determine the Efficacy and Safety of TAK-379 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of multiple doses of
      TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a metabolic disease that has reached epidemic proportions. The global
      incidence of this disease is estimated to increase from 120 million individuals to over 200
      million by the year 2010. In type 2 diabetes, multiple metabolic defects contribute to
      hyperglycemia. These include insulin resistance, inadequate insulin secretion, and excessive
      hepatic glucose production. Nine classes of antihyperglycemic agents are currently approved
      for the treatment of type 2 diabetes (insulin, sulfonylureas, biguanides, alpha-glycosidase
      inhibitors, thiazolidinediones, glinides, glucagon-like peptide analogues, amylin analogues,
      and dipeptidyl peptidase 4 inhibitors). Each class acts by a unique mechanism on 1 or more of
      the metabolic defects.

      Takeda Pharmaceutical Company Limited is developing TAK-379, a non-thiazolidinedione partial
      proliferator-activated receptor agonist for the treatment of type 2 diabetes mellitus. Study
      participation is anticipated to be approximately 4.5 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Animal Toxicity Findings
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Glycosylated Hemoglobin</measure>
    <time_frame>Week 12 or Final Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin.</measure>
    <time_frame>Weeks 4 and 8 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose.</measure>
    <time_frame>Weeks 1, 2, 4, 8 and 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight.</measure>
    <time_frame>Weeks 4, 8 and 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with elevation of alanine aminotransferase greater than three times the Upper Limit of Normal during treatment.</measure>
    <time_frame>Week 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of TAK-379 and its metabolite M-I via a sparse sampling population approach.</measure>
    <time_frame>Week 12 or Final Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TAK-379 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-379 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-379 200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-379</intervention_name>
    <description>TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks</description>
    <arm_group_label>TAK-379 25 mg QD</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-379</intervention_name>
    <description>TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks</description>
    <arm_group_label>TAK-379 100 mg QD</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-379</intervention_name>
    <description>TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks</description>
    <arm_group_label>TAK-379 200 mg QD</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks</description>
    <arm_group_label>Pioglitazone 30 mg QD</arm_group_label>
    <other_name>Actos</other_name>
    <other_name>AD4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Historical diagnosis of type 2 diabetes mellitus without the chronic use of
             antidiabetic therapy and an 8 week history of diet and exercise.

          -  Historical diagnosis of type 2 diabetes mellitus on a stable dose of metformin as
             mono-therapy for at least 3 months prior to screening.

          -  Glycosylated hemoglobin between 7.5% and 10.0%, inclusive.

          -  Fasting C-peptide concentration is greater than or equal to 0.8 ng per mL.

          -  Any other chronic medications which have been stable for at least 4 weeks prior to
             Screening.

          -  Body mass index at Screening is greater than or equal to 23 kg/m2 and less than 45
             kg/m2.

          -  Able and willing to monitor his or her own blood glucose concentrations with a home
             glucose monitor.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Compliance with single-blinded study medication during the run-in phase is at least
             75% and does not exceed 125% based on tablet counts performed by the study staff.

        Exclusion Criteria

          -  Systolic blood pressure is greater than 160 mm Hg, or diastolic pressure is greater
             than 100 mm Hg at repeat measurements.

          -  Any history of bladder cancer or has a history of cancer that has been in remission
             for less than 5 years prior to Screening (a history of basal cell carcinoma or Stage 1
             squamous cell carcinoma of the skin is allowed).

          -  Glycosylated hemoglobin is less than 7.5% and greater than 10.0%.

          -  Creatine phosphokinase is greater than or equal to 5 times the upper limit of normal
             at screening.

          -  Hemoglobin is less than or equal to 12 g per dL for males and less than or equal to 10
             g per dL for females.

          -  Alanine aminotransferase and aspartate aminotransferase are greater than or equal to
             2.5 upper limit of normal.

          -  Total bilirubin is greater than or equal to 1.5 times the upper limit of normal at
             screening.

          -  Serum triglyceride concentration is greater than or equal to 400 mg per dL.

          -  Estimated glomerular filtration rate is less than or equal to 60 mL per min using the
             Modification of Diet in Renal Disease equation or the Cockroft-Gault equation.

          -  Abnormal thyroid-stimulating hormone as defined by central laboratory normals.

          -  Positive test result for hepatitis B surface antigen or hepatitis C antibody.

          -  Urine albumin to creatinine ratio is greater than or equal to 1000 Î¼g per mg at
             screening.

          -  History of microscopic or macroscopic hematuria.

          -  Two consecutive unexplained positive urinalysis dip-stick and greater than or equal to
             3 red blood cells per high-powered field on two consecutive measurements.

          -  History of laser treatment for proliferative diabetic retinopathy within 6 months
             prior to Screening.

          -  Diabetic gastroparesis that in the investigator's opinion is moderate or severe and
             hence may impair absorption of study medication.

          -  The subject has New York Heart Association Class III or IV heart failure.

          -  Has had coronary angioplasty, coronary stent placement, coronary bypass surgery,
             myocardial infarction, unstable angina pectoris, clinically significant abnormal
             electrocardiogram, cerebrovascular accident or transient ischemic attack within 6
             months prior or at Screening.

          -  History of any hemoglobinopathy that may affect determination of glycosylated
             hemoglobin.

          -  Received treatment with probucol within 1 year of randomization.

          -  Donated or received any blood products within 12 weeks prior to Screening.

          -  Received treatment for greater than 7 days within 8 weeks prior to randomization or is
             required to take or continues taking any disallowed medication, prescription
             medication, herbal treatment or over-the counter medication that may interfere with
             evaluation of the study medication, including:

               -  oral or systemically injected glucocorticoids

               -  Prescription or over the counter weight-loss drugs

               -  Peroxisome proliferator-activated receptor agonists, including fibric acid
                  derivatives

               -  Niacin

               -  Ezetemibe

               -  Bile-acid binding agents

               -  warfarin

               -  phenytoin

               -  any alteration in lipid-lowering medication (change in dosage or drug)

          -  Chronically treated with insulin.

          -  Received any investigation drug within 4 weeks prior to Screening.

          -  History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.

          -  Hypersensitive to TAK-379 or its excipients.

          -  History of drug abuse or a history of alcohol abuse within 2 years prior to Screening.

          -  Any other physical or psychiatric disease or condition that in the judgment of the
             investigator may affect life expectancy or may make it difficult to successfully
             manage and follow the subject according to the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.takeda.com/c-t/report-summaries/article_53.html</url>
    <description>Takeda Pharmaceutical Company Limited Website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <disposition_first_submitted>June 20, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 20, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 22, 2016</disposition_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

